{"ok":true,"nota":{"id":"41b3e6a7b227e1d2","slug":"una-nueva-guia-de-salud-amplia-a-millones-de-estadounidenses-el-acceso-41b3e6","titulo":"Una nueva guía de salud amplía a millones de estadounidenses el acceso a medicamentos para diabetes y corazón","resumen":"Analizaron encuestas de salud de adultos de 30 a 79 años en Estados Unidos para estimar cuántos cumplen, según la guía de 2026, requisitos para recibir ciertos medicamentos de diabetes y obesidad que no estaban indicados antes. Describieron el perfil clínico de ese grupo.","fuente":"medrxiv","fuenteNombre":"medRxiv · preprints","color":"#1f7a4d","autor":"Corsi, D. R., Wang, C., Kang, Y. M., Zimerman, A., Agbaje, A. O., Moura, F.","url":"https://www.medrxiv.org/content/10.64898/2026.10.22.26366274v1?rss=1","imagen":"/hoy/portada/41b3e6a7b227e1d2","tema":"salud","subtemas":["medicamentos glp-1","diabetes","guías médicas","enfermedad cardiovascular","obesidad"],"entidades":["Estados Unidos","National Health and Nutrition Examination Survey","American Diabetes Association","medRxiv"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-26T00:00:00.000Z","indexTs":"2026-10-26T14:59:46.399Z","hash":"c8cc86e0d8f16b4c49f802bdeb980d051e07bbb6c15c746f75df02c3cdda95f2","tsa":{"time":"Oct 26 15:00:23 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"Cuando una guía médica cambia, los medicamentos que antes eran para un grupo chico pasan a recetarse a muchísima más gente. Este trabajo calcula que el cambio en Estados Unidos incluye a un número grande de adultos sin diagnóstico de diabetes pero con factores de riesgo. Para alguien de acá, la pregunta es qué pasa cuando esos fármacos, caros y con efectos secundarios, llegan a un sistema de salud que tiene que decidir a quién cubrir. El estudio se basa en datos de 2011 a 2018, así que la realidad actual puede ser distinta.","quienFirma":"Estudio de salud pública en Estados Unidos (preprint en medRxiv)","confianza":"preprint","consulta":null},"sello":{"hash":"c8cc86e0d8f16b4c49f802bdeb980d051e07bbb6c15c746f75df02c3cdda95f2","sello":"176590c4ae0acdd67008ff7f87d3bfd6bb98aee66bc7ff5f674334d99314427c","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6586526,"aleatorio":"c01ce8a1491a0d29f571518fb29f69e0752ae73e6efa32f23b84ec1582e551db","tiempo":"2026-10-26T15:00:00.000Z"},"nist":{"cadena":2,"pulso":2000456,"salida":"F01A54DF5E00A940F69D504F29C5F425BE4FDEAE8472477C275F32B62D9470C2301BCD9D461E368D0DBF5E0AB28553554FF9058427A2B3D8A85AF9ACC30DC53D","tiempo":"2026-10-26T14:59:00.000Z"},"noAntes":"2026-10-26T15:00:00.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 26 15:00:23 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Implications of the 2026 Cardiovascular-Kidney-Metabolic Syndrome Guideline for GLP-1 Receptor Agonist and SGLT2 Inhibitor Eligibility Among US Adults","descripcion":"Background The 2026 cardiovascular-kidney-metabolic (CKM) syndrome guideline broadens recommendations for glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i), but the increment over pre-2026 standards is unknown. We estimated the number and clinical profile of US adults newly eligible under this guideline. Methods Cross-sectional analysis of adults aged 30-79 years in the 2011-2018 National Health and Nutrition Examination Survey. Adults were newly eligible if they met 2026 CKM guideline indications but not pre-2026 American Diabetes Association, American College of Cardiology/American Heart Association heart failure, Kidney Disease: Imp","pubDate":"2026-10-26","url":"https://www.medrxiv.org/content/10.64898/2026.10.22.26366274v1?rss=1"},"indexado":"2026-10-26T14:59:46.399Z"}}